The histone deacetylase inhibitor FR901228 (depsipeptide) restores expression and function of pseudo-null p53

Cancer Biology and Therapy

Volumn 1, Issue 6, 2002, Pages 665-668

  Kitazono, Masaki ^a   Bates, Susan ^a   Fok, Patrick ^a   Fojo, Tito ^a   Blagosklonny, Mikhail V ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

FR901228; Histone deacetylase inhibitors (HDAC inhibitors); p53

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYCLOPEPTIDE; DEPSIPEPTIDE; DOXORUBICIN; FR 901228; HISTONE DEACETYLASE; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PRIMER DNA; PROTEIN MDM2; PROTEIN P53; RNA;

ARTICLE; CARCINOMA; CELL CULTURE; CHEMISTRY; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; THYROID TUMOR; TRANSACTIVATION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DEPSIPEPTIDES; DNA DAMAGE; DNA PRIMERS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; NUCLEAR PROTEINS; PEPTIDES, CYCLIC; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; RNA, NEOPLASM; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037974533     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.317     Document Type: Article

References (16)

1. Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature 2000; 408: 307-10.
2. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE, Fojo T. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocr Metab 1998; 83:2516-22. (Pubitemid 28503056)
3. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000; 19: 3078-85. (Pubitemid 30438464)
4. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-28. (Pubitemid 34742100)
5. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res 1998; 72:141-96. (Pubitemid 27435555)
6. Pogribny IP, Pogribna M, Christman JK, James SJ. Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. Cancer Res 2000; 60:588-94. (Pubitemid 30094555)
7. Schroeder M, Mass MJ. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Commun 1997; 235:403-6. (Pubitemid 27313720)
8. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependent G1 arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83:817-25.
9. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the AS+/I+ symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2000; 86:3430-5. (Pubitemid 32673517)
10. Blagosklonny MV. Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? Bioessays. 2001; 23: 947-53.
11. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, et al. Histone Deacetylase Inhibitors All Induce p21 but Differentially Cause Tubulin Acetylation, Mitotic Arrest, and Cytotoxicity. Mol Cancer Ther 2002 1:937-41.
12. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98:10833-18.
13. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-301.
14. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000; 88:992-7.
15. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94:504-13. (Pubitemid 34411289)
16. Durland-Busbice1 S. and D Reisman D. Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene. Leukemia 2002; 16:2165-67.